JAK-IN-19
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7) . JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC50=7.0, Aurora B pIC50=5.8) [1].
Product Specifications
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak-in-19.html
Solubility
10 mM in DMSO
Smiles
CCC1=CC(O)=C(C=C1C2=CC3=C(C(N[C@H](CO)C)=C2)N=C(N=C3)NCCCCCN(C)C)F
Molecular Formula
C26H36FN5O2
Molecular Weight
469.59
References & Citations
[1]Wellaway CR, et al. Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. J Med Chem. 2022 Jan 13;65 (1) :633-664.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSM040751 200 µg
Recombinant Mouse ALK-2/ACVR1 Protein (His & Fc Tag)
Sign In for Pricing
View Details